<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00553319</url>
  </required_header>
  <id_info>
    <org_study_id>#5502/6569R.</org_study_id>
    <secondary_id>R01DA023652-01</secondary_id>
    <nct_id>NCT00553319</nct_id>
  </id_info>
  <brief_title>Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence</brief_title>
  <acronym>CAMP</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed protocol is a 3 group double-blind, placebo-controlled outpatient study of the
      safety and efficacy of Adderall-XR (ER-MAS) in the treatment of comorbid ADHD and cocaine
      dependence. Since this medication has independently shown promise in helping with ADHD and
      cocaine abuse, we are proposing that it may be successful in the treatment of comorbid ADHD
      and cocaine abuse. We plan to enroll 75 subjects in a 14-week trial. The primary objectives
      of the study are to determine the efficacy of ER-MAS in promoting cocaine abstinence and
      improvement in ADHD symptomology among cocaine-dependent patients with comorbid ADHD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1: To determine the efficacy of ER-MAS in promoting cocaine abstinence and ADHD
      improvement among comorbid ADHD and cocaine-dependent patients.

      Primary Hypothesis: benzoylecgonine positive urine screens will decrease with greatest to
      least reductions from 80mg&gt;60mg&gt;PBO (placebo).

      Hypothesis 2: ADHD-Rating Scale will decrease with greatest to least reductions from
      80mg&gt;60mg&gt;PBO.

      Specific Aim 2: To determine the effect of ER-MAS on improving general functioning and
      impulsivity among comorbid ADHD and cocaine-dependent patients.

      Hypothesis 4: There will be greater improved CGI (clinical global impression scale) scores in
      participants receiving d-AMPH (d-amphetamine) compared to PBO.

      Hypothesis 5: ER-MAS will decrease impulsivity as measured by several self-report (Barratts
      Impulsivity Scale) and behavioral measures (Card Sort, IMT (immediate memory task), DMT
      (delayed memory task), BART) compared to PBO.

      This 14-week, three arm (two medication doses versus PBO), prospective, parallel groups,
      randomized PBO-controlled trial with a lead-in as well as medication run-up and run down
      weeks, will provide clear data on efficacy and safety for definitive Phase III trials, which
      if successful will lead to improved treatment for A-ADHD/S-SUD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Last Three Weeks of Cocaine Abstinence Based on Urine Toxicology Results and Self Reported Use</measure>
    <time_frame>weekly for 14 weeks of trial or for length of participation</time_frame>
    <description>Each week after randomization was scored dichotomously as cocaine positive or negative. Cocaine use was positive if any urine or self-report was positive. Cocaine use was negative if all urines (BE &lt;300 ng/ml) and all self-report were negative. Weeks with no urine or no self-report were designated missing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADHD Symptoms Based on ADHD Rating Scale</measure>
    <time_frame>measured once per week for 14 weeks or length of study participation</time_frame>
    <description>The proportion of subjects exhibiting &gt;30% reduction of AISRS score at last enrollment week compared to week 0</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Adult Attention Deficit Hyperactivity Disorder</condition>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adderall-XR 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adderall-XR 60 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adderall-XR 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adderall-XR 80 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo group</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adderall-XR</intervention_name>
    <description>Adderall-XR 60mg/day</description>
    <arm_group_label>Adderall-XR 60 mg</arm_group_label>
    <other_name>Extended-Release Mixed Amphetamine Salts (Adderall-XR)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adderall-XR</intervention_name>
    <description>Adderall-XR 80mg/day</description>
    <arm_group_label>Adderall-XR 80 mg</arm_group_label>
    <other_name>Extended-Release Mixed Amphetamine Salts (Adderall-XR)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women between the ages of 18-60 who meet DSM-IV criteria for current cocaine
             dependence and adult ADHD (DSM-IV-TR).

          2. Used cocaine at least four days in the past month

          3. Must have a Body Mass Index (BMI) &gt; 18 kg/m2

          4. Alcohol Breathalyzer (BraC) at consent of &lt; 0.04%

          5. Individuals must be capable of giving informed consent and capable of complying with
             study procedures.

          6. Women of child bearing age will be included in the study provided that they are not
             pregnant, based on the results of a blood pregnancy test drawn at the time of
             screening. They must also agree to use a method of contraception with proven efficacy
             and agree not to become pregnant during the study. To confirm this, blood pregnancy
             tests will be repeated monthly. Women will be provided a full explanation of the
             potential dangers of pregnancy while on the study medication. If a woman becomes
             pregnant, the study medication will be discontinued.

        Exclusion Criteria:

          1. Meets DSM-IV-TR criteria for bipolar disorder, schizophrenia or any psychotic disorder
             other than transient psychosis due to drug abuse.

          2. Individuals with any current Axis I psychiatric disorder as defined by DSM-IV-TR
             supported by the SCID-I/P that in the investigator's judgment are unstable or would be
             disrupted by study medication or are likely to require pharmacotherapy during the
             study period.

          3. Individuals with current major depressive disorder.However,individuals who are
             currently stable on a psychotropic medication for three months with a HAM-D &lt;14 may be
             included.

          4. Individuals physiologically dependent on any other drugs (excluding nicotine or
             cannabis) which require medical intervention.

          5. Individuals with current suicidal risk.

          6. Individuals with coronary vascular disease as indicated by history or suspected by
             abnormal ECG, cardiac symptoms, fainting, open-heart surgery and/or arrhythmia, and
             family history of ventricular tachycardia/sudden death.

          7. Unstable physical disorders which might make participation hazardous such as
             uncontrolled hypertension (SBP &gt; 140, DBP&gt; 90, or HR &gt; 100 when sitting quietly),
             acute hepatitis (patients with chronic mildly elevated transaminases &lt; 3x upper limit
             of normal are acceptable), or uncontrolled diabetes.

          8. Individuals with a history of seizures

          9. History of allergic reaction to candidate medication (amphetamine and/or ER-MAS).

         10. Women who are pregnant or nursing.

         11. History of failure to respond to a previous adequate trial of the candidate medication
             for cocaine dependence

         12. Individuals who are legally mandated (e.g., to avoid incarceration, monetary or other
             penalties, etc.) to participate in substance abuse treatment program

         13. History of glaucoma

         14. Individuals who report use of MAOI within 14 days of study start
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frances R Levin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Grabowski</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ambulatory Research Center/Fairview University Psychiatry Dept</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STARS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stars.columbia.edu/</url>
    <description>Substance Treatment and Research Service of Columbia University</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2007</study_first_submitted>
  <study_first_submitted_qc>November 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2007</study_first_posted>
  <results_first_submitted>August 20, 2014</results_first_submitted>
  <results_first_submitted_qc>August 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 1, 2014</results_first_posted>
  <last_update_submitted>May 16, 2016</last_update_submitted>
  <last_update_submitted_qc>May 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>Cocaine</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Adderall</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study consisted of a one week single blind placebo run-in prior to group assignment. 139 participants were enrolled and 126 were randomized following the placebo run-up</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo group</description>
        </group>
        <group group_id="P2">
          <title>Adderall-XR 60 mg</title>
          <description>Adderall-XR 60 mg
Adderall-XR: Adderall-XR 60mg/day</description>
        </group>
        <group group_id="P3">
          <title>Adderall-XR 80 mg</title>
          <description>Adderall-XR 80 mg
Adderall-XR: Adderall-XR 80mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>wanted treatment elsewhere</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>incarceration</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>moved</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Description of 126 participants randomized to study arms.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo group</description>
        </group>
        <group group_id="B2">
          <title>Adderall-XR 60 mg</title>
          <description>Adderall-XR 60 mg
Adderall-XR: Adderall-XR 60mg/day</description>
        </group>
        <group group_id="B3">
          <title>Adderall-XR 80 mg</title>
          <description>Adderall-XR 80 mg
Adderall-XR: Adderall-XR 80mg/day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="126"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>YEARS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.3" spread="7.4"/>
                    <measurement group_id="B2" value="43.9" spread="7.5"/>
                    <measurement group_id="B3" value="38.4" spread="8.6"/>
                    <measurement group_id="B4" value="40.4" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Days of cocaine use (prior 28 days)</title>
          <units>DAYS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.3" spread="7.5"/>
                    <measurement group_id="B2" value="12.4" spread="7.8"/>
                    <measurement group_id="B3" value="11.3" spread="7.0"/>
                    <measurement group_id="B4" value="11.7" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Last Three Weeks of Cocaine Abstinence Based on Urine Toxicology Results and Self Reported Use</title>
        <description>Each week after randomization was scored dichotomously as cocaine positive or negative. Cocaine use was positive if any urine or self-report was positive. Cocaine use was negative if all urines (BE &lt;300 ng/ml) and all self-report were negative. Weeks with no urine or no self-report were designated missing.</description>
        <time_frame>weekly for 14 weeks of trial or for length of participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo group</description>
          </group>
          <group group_id="O2">
            <title>Adderall-XR 60 mg</title>
            <description>Adderall-XR 60 mg
Adderall-XR: Adderall-XR 60mg/day</description>
          </group>
          <group group_id="O3">
            <title>Adderall-XR 80 mg</title>
            <description>Adderall-XR 80 mg
Adderall-XR: Adderall-XR 80mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Last Three Weeks of Cocaine Abstinence Based on Urine Toxicology Results and Self Reported Use</title>
          <description>Each week after randomization was scored dichotomously as cocaine positive or negative. Cocaine use was positive if any urine or self-report was positive. Cocaine use was negative if all urines (BE &lt;300 ng/ml) and all self-report were negative. Weeks with no urine or no self-report were designated missing.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ADHD Symptoms Based on ADHD Rating Scale</title>
        <description>The proportion of subjects exhibiting &gt;30% reduction of AISRS score at last enrollment week compared to week 0</description>
        <time_frame>measured once per week for 14 weeks or length of study participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo group</description>
          </group>
          <group group_id="O2">
            <title>Adderall-XR 60 mg</title>
            <description>Adderall-XR 60 mg
Adderall-XR: Adderall-XR 60mg/day</description>
          </group>
          <group group_id="O3">
            <title>Adderall-XR 80 mg</title>
            <description>Adderall-XR 80 mg
Adderall-XR: Adderall-XR 80mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>ADHD Symptoms Based on ADHD Rating Scale</title>
          <description>The proportion of subjects exhibiting &gt;30% reduction of AISRS score at last enrollment week compared to week 0</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During 14 weeks of trial or length of study participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo group</description>
        </group>
        <group group_id="E2">
          <title>Adderall-XR 60 mg</title>
          <description>Adderall-XR 60 mg
Adderall-XR: Adderall-XR 60mg/day</description>
        </group>
        <group group_id="E3">
          <title>Adderall-XR 80 mg</title>
          <description>Adderall-XR 80 mg
Adderall-XR: Adderall-XR 80mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>rape</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Racing heart</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Fidgety/Jittery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The dropout rate was relatively low, however, there were dropouts, and this does introduce uncertainly into the outcome assessment. Since all patients received CBT we cannot conclude whether CBT is necessary to derive benefit from the medication.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Frances R. Levin, M.D.</name_or_title>
      <organization>Columbia University</organization>
      <phone>646-774-6137</phone>
      <email>frl2@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

